Cinnarizine
Mechanism :
Cinnarizine inhibits contractions of vascular smooth muscle cells by blocking L-type and T-type voltage gated calcium channels. Cinnarizine has also been implicated in binding to dopamine D2 receptors, histamine H1 receptors, and muscarinic acetylcholine receptors.
Indication :
- Vertigo/Meniere’s disease
- Motion sickness
Contraindications :
Hypersensitivity to cinnarizine
Children <5 years of age
Dosing :
Use in children 5-12 years.
Vertigo:
15 mg 3 times a day PO.
Motion sickness
15 mg oral 2 hours before travel and then 7.5 mg PO every 8 hours during the journey.
Adverse Effect :
Somnolence, indigestion, headache, dry mouth, increased sweating, weight gain, mouth sores, rash, jaundice, tremors, restlessness.
Interaction :
No significant interactions found.
Renal Dose :
Dose in Renal Impairment GFR (mL/min)
| 20-50 | Dose as in normal renal function |
| 10-20 | Dose as in normal renal function |
| <10 | Dose as in normal renal function |
Dose in Patients undergoing Renal Replacement Therapies
| CAPD | Unlikely to be dialysed. Dose as in normal renal function |
| HD | Unlikely to be dialysed. Dose as in normal renal function |
| HDF/High flux | Unknown dialysability. Dose as in normal renal function |
| CAV/VVHD | Unlikely to be dialysed. Dose as in normal renal function |
Hepatic Dose :
No dosage adjustments are recommended.